Abstract
PROpel: Efficacy of abiraterone + olaparib vs. abiraterone + placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have